In sharp contrast, RRM1 T52A expression strongly enhanced the inhibitory effects of TMZ on brain tumors (Fig. 6f and Supplementary Fig. 9a, b) with corresponding extension of survival time (Fig. 6g). Here, RRM1 is linked to brain neoplasm.